showed a trendP = 0.10
The patients with CD30-negative showed a trend toward improved OS and longer PFS versus those with CD30-positive (median OS: 71.5 vs. 25.0 months, P = 0.10; median 1 L PFS: 13.7 vs. 9.1 months; P = 0.14; Figs.
The patients with CD30-negative showed a trend toward improved OS and longer PFS versus those with CD30-positive (median OS: 71.5 vs. 25.0 months, P = 0.10; median 1 L PFS: 13.7 vs. 9.1 months; P = 0.14; Figs.